Tsutsumi H, Iwama E, Ibusuki R, Shimauchi A, Ota K, Yoneshima Y, et al. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Lung Cancer. 2023;175:101-111 pubmed publisher

Prieto Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, et al. USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. Mol Oncol. 2022;: pubmed publisher

Song X, Tang W, Peng H, Qi X, Li J. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Invest New Drugs. 2021;: pubmed publisher

Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, et al. Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Sci. 2021;112:1963-1974 pubmed publisher

Vaishnavi A, Scherzer M, Kinsey C, Parkman G, Truong A, Ghazi P, et al. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep. 2020;32:107994 pubmed publisher

Kim D, Park S, Kim D, Jeong M, Noh J, Kwon Y, et al. Direct visualization of single-molecule membrane protein interactions in living cells. PLoS Biol. 2018;16:e2006660 pubmed publisher

Du W, Ni L, Liu B, Wei Y, Lv Y, Qiang S, et al. Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer. Oncogenesis. 2018;7:36 pubmed publisher

Weng Y, Fan X, Bai Y, Wang S, Huang H, Yang H, et al. SLC2A5 promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. Cell Death Discov. 2018;4:38 pubmed publisher

Giuliano C, Lin A, Smith J, Palladino A, Sheltzer J. MELK expression correlates with tumor mitotic activity but is not required for cancer growth. elife. 2018;7: pubmed publisher

Song X, Qi X, Wang Q, Zhu W, Li J. A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Am J Cancer Res. 2017;7:1884-1898 pubmed

Xu Y, Wang X, Chen Y, Chen S, Yang X, Sun Y, et al. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer. Theranostics. 2017;7:974-986 pubmed publisher

Nakamura Y, Ohler Z, Householder D, Nagaya T, Sato K, Okuyama S, et al. Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer. Mol Cancer Ther. 2017;16:408-414 pubmed publisher

Ku B, Bae Y, Koh J, Sun J, Lee S, Ahn J, et al. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. Invest New Drugs. 2016;34:407-15 pubmed publisher

Unni A, Lockwood W, Zejnullahu K, Lee Lin S, Varmus H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. elife. 2015;4:e06907 pubmed publisher

Whitsett T, CHENG E, Inge L, Asrani K, Jameson N, Hostetter G, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012;181:111-20 pubmed publisher

Rossi M, Colecchia D, Iavarone C, Strambi A, Piccioni F, Verrotti di Pianella A, et al. Extracellular signal-regulated kinase 8 (ERK8) controls estrogen-related receptor ? (ERR?) cellular localization and inhibits its transcriptional activity. J Biol Chem. 2011;286:8507-22 pubmed publisher

Greulich H, Chen T, Feng W, Janne P, Alvarez J, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2:e313 pubmed